Risk factors
Anavex Life Sciences (AVXL) risk factors
Item 1A of every Anavex Life Sciences Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks4 new1 dropped12 reworded
Anavex added regulatory and trade risks, including a negative trend vote from the EMA's CHMP for blarcamesine.
Filed Nov 25, 2025 - FY2024 10-K risk factors44 risks
Anavex Life Sciences has accumulated a deficit of approximately $336 million with no commercial revenue and depends entirely on future funding to survive. The company faces heavy regulatory uncertainty for its drug candidates like ANAVEX®2-73 in neurodegenerative disorders and relies heavily on patent protection.
Filed Dec 23, 2024